A Brief Summary of PET Imaging of Dopaminergic System

Ismet Sarikaya

doi:10.1055/s-0045-1802590

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY 4.0 · World J Nucl Med 2025; 24(01): 001-002
DOI: 10.1055/s-0045-1802590

Editorial

A Brief Summary of PET Imaging of Dopaminergic System

Ismet Sarikaya

¹Department of Nuclear Medicine, Kirklareli University Faculty of Medicine, Kirklareli, Türkiye

References
1 Franco R, Reyes-Resina I, Navarro G. Dopamine in health and disease: much more than a neurotransmitter. Biomedicines 2021; 9 (02) 109
2 Kilbourn MR. ¹¹C- and ¹⁸F-radiotracers for in vivo imaging of the dopamine system: past. Biomedicines 2021; 9 (02) 108
3 Sarikaya I. PET imaging of dopaminergic system and clinical applications. Clin Transl Imaging 2024; 12: 717-729
4 Morbelli S, Esposito G, Arbizu J. et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging 2020; 47 (08) 1885-1912
5 la Fougère C, Pöpperl G, Levin J. et al. The value of the dopamine D2/3 receptor ligand ¹⁸F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 2010; 51 (04) 581-587
6 Klein JC, Eggers C, Kalbe E. et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74 (11) 885-892
7 Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995; 118 (Pt 3): 689-696
8 Sarikaya I. Biology of cancer and PET imaging: pictorial review. J Nucl Med Technol 2022; 50: 81-89
9 Taïeb D, Hicks RJ, Hindié E. et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019; 46 (10) 2112-2137
10 Piccardo A, Morana G, Puntoni M. et al. Diagnosis, treatment response, and prognosis: the role of ¹⁸F-DOPA PET/CT in children affected by neuroblastoma in comparison with ¹²³I-mIBG scan: the first prospective study. J Nucl Med 2020; 61 (03) 367-374
11 Evangelista L, Cuppari L, Bellu L. et al. Comparison between ¹⁸F-Dopa and ¹⁸F-Fet PET/CT in patients with suspicious recurrent high grade glioma: a literature review and our experience. Curr Radiopharm 2019; 12 (03) 220-228
12 Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. ¹⁸F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001; 28 (01) 64-71
13 Schillaci O. ¹⁸F-DOPA and other radiopharmaceuticals for imaging unknown primary neuroendocrine tumors. J Nucl Med 2014; 55 (03) 357-359
14 States LJ, Davis JC, Hamel SM, Becker SA, Zhuang H. ¹⁸F-6-fluoro-l-Dopa PET/CT imaging of congenital hyperinsulinism. J Nucl Med 2021; 62 (Suppl. 02) 51S-56S
15 Leroy-Freschini B, Amodru V, Addeo P. et al. Early ¹⁸F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. Eur J Nucl Med Mol Imaging 2019; 46 (03) 686-695